According to filings with the U.S. Securities and Exchange Commission, Immunophotonics is raising up to $4,000,000.00 in new funding. Sources indicate that as part of senior management Chief Executive Officer, Luke Alleruzzo played a key role in securing the recent investment and it will aid in aggressively expanding the company, as well as broaden and accelerate product development.

About Immunophotonics
Immunophotonics is a privately owned clinical stage biotech that has discovered a novel and simple approach to achieve patient-specific anticancer immunity. The company is currently developing its first asset, the immune-modulating proprietary carbohydrate polymer IP-001 for the treatment of solid tumor cancers. IP-001 has unique physio-chemical and immunological properties that allows it to ignite a systemically active cancer immunotherapy from a routine tumor ablation; a minimal invasive intervention that destroys tumors and in doing so liberates tumor antigens. IP-001 enhances interactions of tumor antigens with the immune system, improves the motility of tumor infiltrating T cells, promotes their surveillance of tumor tissue and can generate long-term protective immunity.

To learn more about Immunophotonics, visit http://immunophotonics.com/

Contact:
Luke Alleruzzo, Chief Executive Officer
314-501-1919
https://www.linkedin.com/in/lualleruzzo/

SOURCE: http://www.intelligence360.io
Copyright (c) 2024 SI360 Inc. All rights reserved.